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Background: Antimicrobial resistance (AMR) is a major global public health concern and its surveillance is a
fundamental tool for monitoring the development of AMR. In 1998, the Nepalese Ministry of Health (MOH)
launched an Infectious Disease (ID) programme. The key components of the programme were to establish a
surveillance programme for AMR and to develop awareness among physicians regarding AMR and rational drug
usage in Nepal.
Methods: An AMR surveillance programme was established and implemented by the Nepalese MOH in partnership
with the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) from 1998 to 2003. From 2004
to 2012, the programme was integrated and maintained as a core activity of the National Public Health Laboratory
(NPHL) and resulted in an increased number of participating laboratories and pathogens brought under
surveillance. The main strategies were to build national capacity on isolation, identification and AMR testing of
bacterial pathogens, establish laboratory networking and an External Quality Assessment (EQA) programme,
promote standardised recording and reporting of results, and to ensure timely analysis and dissemination of data
for advocacy and national policy adaptations. The programme was initiated by nine participating laboratories
performing AMR surveillance on Vibrio cholerae, Shigella spp., Streptococcus pneumoniae, Haemophilus influenzae, and
Neisseria gonorrhoeae.
Results: The number of participating laboratories was ultimately increased to 13 and the number of pathogens
under surveillance was increased to seven (Salmonella spp. was added to the surveillance programme in 2002
and extended spectrum β-lactamase producing Escherichia coli in 2011). From 1999 to 2012, data were available
on 17,103 bacterial isolates. During the AMR programme, we observed changing trends in serovars/ species for
Salmonella spp., Shigella spp. and V. cholerae and changing AMR trend for all organisms. Notably, N. gonorrhoeae
isolates demonstrated increasing resistance to ciprofloxacin. Additionally, the performance of the participating
laboratories improved as shown by annual EQA data evaluation.
Conclusions: This Nepalese AMR programme continues and serves as a model for sustainable surveillance of AMR
monitoring in resource limited settings.
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Antimicrobial resistance (AMR) in bacterial pathogens
reduces the effectiveness of antimicrobial agents leading
to increased morbidity, mortality and healthcare costs
[1]. While the eradication of AMR is not realistic, sig-
nificant delay in development of AMR can be achieved
by rational antimicrobial use [2]. In Nepal, over-the-
counter availability, dispensing of antimicrobials without
professional consultation, inappropriate usage and the
use of antimicrobials with low potency as a result of
poor manufacturing and storage conditions or counter-
feiting are common, and encourage AMR development
[3,4]. Policies and regulations that support appropriate
and rational use of antimicrobials are key to the long-
term interventions for reducing AMR. Although many
global and local strategies and interventions have been
developed for containing AMR, surveillance of AMR re-
mains fundamental to combating resistance [5,6]. The
World Health Organisation (WHO) recommends that
each member-state establish a national surveillance pro-
gramme of AMR for selected bacteria to monitor drug
susceptibility in relevant organisms [7]. In Nepal, there are
major challenges in implementing such a programme.
This is due to the following factors: lack of appropriately
trained personnel, frequent transfer of staff, poor access
to good quality reagents, inadequate storage facilities
of reagents, frequent power failure, limited funding as
a result of competing priorities, and frequent policy
changes. The situation has been compounded by political
instability and insurgency. In this report, we present our
experience of implementing a sustainable national AMR
surveillance programme in Nepal.
Methods
Local setting
Nepal is a low-income country (as determined by the
World bank) with a poorly organised healthcare delivery
system, suffering from resource limitations. Political
unrest and the Maoist insurgency from 2001 to 2008
affected many sectors of life including sustainable health
care delivery. Furthermore, pharmaceutical manufactur-
ing and importation is poorly regulated and drugs,
including antimicrobials, are available without prescrip-
tion, and antimicrobial consumption on sub-therapeutic
dose, for sub-optimal duration is common. Additionally,
pharmaceuticals are often stored in sub-standard condi-
tions, compromising product quality. The public health
care system in Nepal has a limited laboratory capacity
for bacterial culture and AMR testing (available only at
some regional hospitals).
Response
In 1998, the Ministry of Health (MOH), Nepal and the
United States Agency for International Development (USAID)launched an Infectious Disease (ID) control programme to
strengthen national capacity for prevention and control of
priority infectious diseases. The goals were to develop a
sustainable national surveillance of AMR, develop awareness
among physicians regarding AMR and rational drug use, to
establish a microbiology quality assurance programme and
to systematise record keeping system with data dissemin-
ation. The programme in Nepal was implemented by the
International Centre for Diarrhoeal Disease Research,
Bangladesh (ICDDR, B) Dhaka, Bangladesh in collaboration
with Rational Pharmaceutical Management Project (RPM)
Arlington, VA, USA. The programme was approved by
ICDDR, B research review committee and ethical review
committee. The programme started with a participatory
planning workshop to build the programme team and to
establish a forum for stakeholders (MOH/ Government of
Nepal and key organisations -USAID, Nepal andWashington;
RPM; USCDC (United States Center for Disease Control and
Prevention, Atlanta, Georgia);ICDDR, B; and WHO/Nepal).
The workshop focused on development of strategies and ap-
proaches of the programme. The programme was designed
for selected enteric pathogens (Vibrio cholerae and Shigella
spp.), respiratory pathogens (Streptococcus pneumoniae and
Haemophilus influenzae) and sexually transmitted pathogen
(Neisseria gonorrhoeae). The National Public Health Labora-
tory (NPHL) and the Epidemiology and Disease Control
Division (EDCD) were identified as the national coordinat-
ing laboratory and the national focal point for the pro-
gramme, respectively.
A baseline assessment of 13 laboratories (in the central,
eastern, western regions) was conducted in November
1998 using a pre-defined (location, infrastructure, human
resource, instrumentation, shipping of bacterial isolates
and willingness to share bacterial isolates and data) as-
sessment tool and nine laboratories were selected to im-
plement the programme. A national capacity building
initiative through training and workshops were conducted
by ICDDR, B and NPHL at NPHL, ICDDR, B and at the
participating laboratories, through 1999–2012. The goal
was to develop a pool of trainers to train technologists
to compensate for transfer, replacement or separation
and to facilitate expansion of trained staff. Training
included i) the training of trainers, ii) bacterial isolation and
Minimum Inhibitory Concentration (MIC) determination,
iii) the isolation, identification and MIC determination of
Salmonella Typhi, N. gonorrhoeae, S. pneumoniae and H.
influenzae and iv) holding annual refresher training
workshops. Additionally, consensus workshops and annual
meetings were organised during 1999 to 2004. Laboratory
testing and procedures were standardised by developing
and implementing Standard Operating Procedures (SOPs)
for the isolation, identification and AMR testing of the
selected pathogens, reporting results, data/record keeping
systems, AMR reporting formats, documentation and
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was supported with bacterial culture media, antimicrobial
susceptibility discs and antisera at the outset and was en-
couraged to incorporate the supplies for surveillance of
AMR in their annual procurement list. NPHL was also sup-
ported with autoclaves, computers and a -86°C freezer.
Each laboratory was also supplied with ATCC (American
type culture collection) strains for internal quality control
(QC).
Each participating laboratory isolated and identified
selected pathogens (all consecutive isolates) and performed
AMR testing (selected antimicrobial agents for each patho-
gen using disk diffusion method [8]) and reported data
monthly to NPHL and ICDDR, B and sent the isolates to
NPHL. At NPHL, all isolates were verified for identification
and susceptibility testing and stored at −86°C for future
analysis. As very few patients were attending the partici-
pating laboratories for sexually transmitted disease (STD)
symptoms, isolation of N. gonorrhoeae was established at
specific STD clinics at Damak and Hetauda. To strengthen
partnerships and networking among the laboratories, train-
ing visits between NPHL and participating laboratories
were organised. Meetings were also organised among par-
ticipating laboratories to discuss surveillance programme













Figure 1 Geographical distribution and network of laboratories unde
Laboratory; BH, Bir Hospital; PH, Patan Hospital; KCH, Kanti Children’s Hospi
Institute of Health Sciences; WRH, Western Regional Hospital; MTH, Manipa
Hospital (included in 2006); DH, Dhulikhel Hospital (included in 2008) and K
Kathmandu Medical College and Teaching Hospital (included in 2010).challenges in implementation of the programme. Addition-
ally, ICDDR, B and NPHL team routinely visited the labora-
tories and provided technical assistance to improve the
performance. A two-tier system of External Quality Assess-
ment (EQA) programme and inter-laboratory comparison
was implemented to ensure quality. The EQA programme
included ICDDR, B (1999–2003)/NHPL (2003–2012) send-
ing two isolates to each of the laboratories every three
months, and the inter-laboratory comparison included
retesting of 10% isolates at ICDDR, B/NPHL (1999–2003)
and NHPL (2003–2012). The WHO scoring system was
followed for the EQA and confidential evaluation reports
were sent to the laboratories.
Results and discussion
The AMR surveillance programme was initiated by a
network of nine laboratories in 1999. Lumbini Zonal
Hospital (LZH), Butwal, Dhulikhel Hospital (DH), Kabhre,
Kathmandu Model Hospital, Katmandu and Kathmandu
Medical College and Hospital, Kathmandu, joined the
programme in 2006, 2008, 2009 and 2011 respectively
(Figure 1). The programme started with five pathogens and
Salmonella spp. was included in the surveillance in 2002,
following an outbreak of enteric fever due to a multiple
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MH, Kathmandu Model Hospital (included in 2009), KMCTH,
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was added to the programme in 2009. From 1999 through
2003, ICDDR, B procured and supplied antisera, bacterial
culture media and antimicrobial susceptibility discs for the
programme. After 2003, the procurement of supplies was
integrated into the annual laboratory procurement
programme of NPHL.
A total of 10 training workshops and five consensus meet-
ings among participating laboratories were organised during
1999 to 2003, and from 2004 to 2012 annual refresher train-
ing was organised among participating laboratories. Training
workshops mainly focused on improving the skill of local
technicians, technology transfer and creating a pool of local
technicians to compensate for transfer and retirements.Table 1 Number of different bacterial pathogens isolated and









1999 61 8 55 2
2000 244 33 155 25
2001 4 40 141 57
2002 25 48 54 115
2003 78 36 56 56
2004 290 43 83 25
2005 62 51 132 60
2006 32 23 92 38
2007 204 37 120 185
2008 148 17 189 136
2009 109 20 213 101
2010 45 9 165 35
2011 1 11 163 71
2012 35 14 257 27
Total 1338 390 1875 933
Susceptibility of all consecutive isolates collected in the participating laboratories w
*Susceptibilities for tetracycline, erythromycin, ciprofloxacin, furazolidone, cotrimoxa
changing antimicrobial resistance trends was observed for V. cholerae, yet the El To
**Susceptibilities for ampicillin, ciprofloxacin, cotrimoxazole, nalidixic acid, mecillina
species during 1999 – 2004 and S. flexneri during 2005 – 2009. S. dysenteriae was pr
Ciprofloxacin resistant S. dysenteriae was common before 2005, which then decreas
33-75% in shigella isolates was found with individual temporal and species variation
***Susceptibilities for penicillin, ampicillin, erythromycin, ciprofloxacin, cotrimoxazol
maintained a persistently high level of resistance (58-74%) to cotrimoxazole. Amoxi
strains were isolated from children below 15 years with 21% of all isolates from chi
****Susceptibilities for penicillin, ampicillin, amoxi-clav, ciprofloxacin, cotrimoxazole
determined. Cotrimoxazole resistance remained high (up to 60%) while more than
and erythromycin. Penicillin resistance reached 100% in 2010.
*****Susceptibilities for penicillin, tetracycline, ciprofloxacin, spectinomycin, azithrom
for ciprofloxacin (14-30%) and tetracycline (more than 70%). Ceftriaxone remained
******Susceptibilities for ampicillin, tetracycline, ciprofloxacin, cotrimoxazole, nalidix
resistance of S. Typhi and S. Paratyphi A to nalidixic acid was observed (the resistan
of S. Paratyphi A increased annually indicating changing epidemiology. Multi drug
at a time among salmonella isolates declined from 2002 onwards, and newly emerg
nalidixic acid with additional resistance to tetracycline and cotrimoxazole) were ide
again from 2009 (7%) and 2010 (8%). Chloromphenicol sensitivity re-emerged (96%
*******All isolates exhibited 100% resistance towards quinolones viz. norfloxacin an
to be susceptible to gentamicin (67%) followed by vhloramphenicol(66%) and amik
NI, not included in the surveillance.Consensus meetings were aimed to i) incorporate local in-
novative ideas generated by local experts (e.g. incorporating
salmonella in the surveillance), and ii) encourage participat-
ing laboratory management in incorporating surveillance
supplies in their respective laboratory procurement plan.
Annual meetings were organised among key partners and
stakeholders of the programme to i) communicate the
progress and the key challenges ii) receive input from all key
partners, iii) advocate for increasing the budget for the
laboratories and iv) minimise the transfer of surveillance
programme staff.
During 1998 to 2003, the ICDDR, B provided technical
support to NPHL to function as the national coordination








18 NI NI 144
36 NI NI 493
21 NI NI 263
9 44 NI 295
22 745 NI 993
2 510 NI 953
14 692 NI 1010
5 1611 NI 1801
5 1512 NI 2063
16 1697 NI 2203
13 1307 14 1764
7 1525 86 1872
6 1018 76 1346
7 1102 447 1889
181 11763 623 17103
as determined by disk diffusion method [8].
zole, nalidixic acid and ampicillin were determined; a shift in serovars with
r biotype remained predominant.
m, and azithromycin were determined. S. dysenteriae was the predominant
edominant in eastern Nepal, while S. flexneri dominated in the western Nepal.
ed up to 2007, and re-emerged in 2008. An overall multiresistance rate of
s from S. dysenteriae to S. flexneri.
e, chloramphenical, and ceftriaxone were determined; S. pneumoniae
cillin resistance increased to 13% in 2010. One-third of the pneumococcal
ldren less than five years of age.
, erythromycin, chloramphenicol, azithromycin and ceftriaxone were
a quarter of the isolates were resistant to at least ampicillin, penicillin
ycin and ceftriaxone were determined. Prevalence of resistance was high
100% susceptible.
ic acid, chloramphenicol, and ceftriaxone were determined. Increasing
ce rate was higher among S. Paratyphi A than among S. Typhi. The prevalence
resistance (MDR-resistance to ampicillin, chloramphenicol and cotrimoxazole)
ed MDR isolates (resistant to fluoroquinolone [ciprofloxacin, ofloxacin] and
ntified in 2005, 2006, 2008, 2009 and 2010. MDR phenomenon has increased
in 2010).
d ofloxacin followed by 99% resistance to ciprofloxacin. ESBL E.coli were found
acin(59%).
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2008, NPHL integrated the surveillance of AMR as one of
its core activities to ensure the sustainability of the
programme.
During 1999–2012, a total of 17,103 bacterial isolates
(1,338 V. cholerae, 390 Shigella spp., 1,875 S. pneumoniae,
933 H. influenzae, 118 N. gonorrhoeae, 11,763 Salmonella
spp., and 623 E. coli) were reported and had corresponding
AMR data generated (Table 1) [10-18]. Performance for
identification and antimicrobial susceptibility testing of the
participating laboratories improved (Figure 2). NPHL,
EDCD and the other participating laboratories dissemi-
nated the surveillance data through workshops, scientific
conferences and journal publications. The AMR surveil-
lance programme contributed to changing the national case
management guidelines and national policies for surveil-
lance of several diseases.
The training programme and consensus meeting contrib-
uted significantly to national laboratory capacity building,
standardisation and use of protocols for selected pathogens,
and added new pathogens for surveillance as per local need.
The programme also helped NPHL to build capacity for
storing the isolates in Nepal and thereby create a sense of
ownership of the programme (isolates and data generated
through the programme). The programme created a pool
of trained technicians who can compensate for transfer
and separation of staff and contribute to expansion of
programme staff. Stakeholders’ meeting contributed in
motivating the MOH, Nepal to increase the resources for
laboratories, and incorporating the programme as a core
activity of the NPHL and participating laboratories. The
programme laid a solid platform for conducting laboratory-























Figure 2 EQA evaluation of the participating laboratories for organism
testing (solid columns) during 2000 to 2008. The EQA programme inclu
every quarter for organism identification and antimicrobial susceptibility tedissemination programme helped to establish a forum for
discussion on surveillance of AMR in Nepal.
The surveillance of AMR programme in Nepal contrib-
uted to some significant policy changes with regard to
choice of antimicrobials and vaccination strategies. The
national STD case management guidelines in Nepal recom-
mended a change from ciprofloxacin to cefixime as the
first-line therapy for the management of uncomplicated
gonococcal infection. Also, as more than 20% of pneumo-
coccal isolates were from children below the age of five
years, this facilitated evidence-based decision by the MOH
to formulate a strategy for pneumococcal vaccination for
Nepalese children [15]. Cotrimoxazole has been previously
supplied to health posts and sub-health posts for treatment
of respiratory infections. As the surveillance programme
revealed that most of the S. pneumoniae and H. influenzae
isolates were resistant to cotrimoxazole, the health author-
ities initiated discussion on suitable alternatives for cotri-
moxazole for respiratory infections in Nepal. Ciprofloxacin
is no longer considered as the drug of choice for treating
salmonella infections, because of reduced susceptibility,
even though it appears susceptible in vitro. In this example,
laboratory technicians were guided to use nalidixic acid re-
sistance as a proxy screening test to determine reduced
fluoroquinolone susceptibility [19] and physicians were also
advised to interpret the susceptibility results based on this
screening test to prevent treatment failure of enteric fever.
Conclusion
This study illustrates the success of implementing a AMR
surveillance programme in a resource poor developing
country. To ensure the quality of the surveillance of AMR








2004 2005 2006 2007 2008
Year
identification (striped columns) and antimicrobial susceptibility
ded sending two isolates to each of the participating laboratories
sting.
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motivation of the laboratory staff are vital. Programme
planning should pay attention to data collection, compil-
ation and storage; an electronic data collection system and
appropriate data backup system can reduce the workload of
manual/semi electronic labour-intensive system. The sur-
veillance of AMR has continued in Nepal with minimal
external financial support; financial dependency on donors
should be eliminated. The expansion of laboratory network,
gradual incorporation of other pathogens as per local need
and resistance testing for additional antimicrobials may be
necessary. Analysis and timely feedback of surveillance of
AMR data and findings can ensure the use of the data to
guide local practices. Attention should be paid to human
resources, training, standardisation, capacity building and
ensuring the ownership of the programme (isolates and
data) by the participating laboratories to ensure sustain-
ability.
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